Acute Radiation Syndrome (ARS) is an area of high unmet need, as there are no current FDA approved therapies. The unique mechanism of action of TPO-7630 increases the cells’ ability to deal with radiation-induced oxidative cell damage, promoting its survival. TPO-7630 is being developed as a therapeutic to be given before (prophylactic) or after (mitigator) radiation exposure to treat civilians, military personnel, and first responders.

Additional RLIP76 protein protects the cell from radiation exposure.